PMPablo Miguéns-Suárez

Pablo Miguéns-Suárez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pablo Miguéns-Suárez has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Francisco Javier Salgado

    BioLympho Research Group, Department of Biochemistry and Molecular Biology, Faculty of Biology-Biological Research Centre (CIBUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain

    2 shared publications
  • Juan José Nieto-Fontarigo

    BioLympho Research Group, Department of Biochemistry and Molecular Biology, Faculty of Biology-Biological Research Centre (CIBUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain

    2 shared publications
  • Laura Martelo-Vidal

    BioLympho Research Group, Department of Biochemistry and Molecular Biology, Faculty of Biology-Biological Research Centre (CIBUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain

    2 shared publications
  • Sara Vázquez-Mera

    BioLympho Research Group, Department of Biochemistry and Molecular Biology, Faculty of Biology-Biological Research Centre (CIBUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain

    2 shared publications
  • Susana Belen Bravo

    Proteomic Unit Health Research Institute of Santiago de Compostela (IDIS) Santiago de Compostela Spain

    2 shared publications
  • Vicente Domínguez-Arca

    Biosystems and Bioprocess Engineering (Bio2Eng) Group Institute of Marine Research of the Spanish Research Council IIM‐CSIC Vigo Spain

    2 shared publications

Latest Publications

  • Open Access

    Urinary Proteome and Exosome Analysis Protocol for the Discovery of Respiratory Diseases Biomarkers

    by Laura Martelo-Vidal, Sara Vázquez-Mera, Pablo Miguéns-Suárez, Susana Belén Bravo-López, Heidi Makrinioti, Vicente Domínguez-Arca, Javier De-Miguel-Díez, Alberto Gómez-Carballa, Antonio Salas, Francisco Javier González-Barcala, et al.

    This study aims to develop a protocol for respiratory disease-associated biomarker discovery by combining urine proteome studies with urinary exosome components analysis (i.e., miRNAs). To achieve this, urine was DTT treated to decrease uromodulin, then concentrated and ultracentrifuged. Proteomic analyses of exosome-free urine were performed using LC-MS/MS. Simultaneously, miRNA expression from urine exosomes was measured using either RTqPCR (pre-amplification) or nCounter Nanostring (non-amplication) analyses. We detected 548 different proteins in exosome-free urine samples (N = 5) with high confidence (FDR < 1%), many of them being expressed in different non-renal tissues. Specifically, lung-related proteins were overrepresented (Fold enrichment = 1.31; FDR = 0.0335) compared to whole human proteome, and 10–15% were already described as protein biomarkers for several pulmonary diseases. Urine proteins identified belong to several functional categories important in respiratory pathology. We could confirm the expression of miRNAs previously connected to respiratory diseases (i.e., miR-16-5p, miR-21-5p, miR-146a-5p, and miR-215-5p) in urine exosomes by RTqPCR. Finally, we detected 333 miRNAs using Nanostring, 15 of them up-regulated in T2high asthma (N = 4) compared to T2low asthma (N = 4) and healthy subjects (N = 4). Therefore, this protocol combining the urinary proteome (exosome free) with the study of urinary exosome components (i.e., miRNAs) holds great potential for molecular biomarker discovery of non-renal and particularly respiratory pathologies.

  • Open Access

    Signature Proteins in Small Extracellular Vesicles of Granulocytes and CD4+ T-Cell Subpopulations Identified by Comparative Proteomic Analysis

    by Sara Vázquez-Mera, Pablo Miguéns-Suárez, Laura Martelo-Vidal, Sara Rivas-López, Lena Uller, Susana B. Bravo, Vicente Domínguez-Arca, Xavier Muñoz, Francisco J. González-Barcala, Juan J. Nieto Fontarigo, et al.

    Several studies have described the proteomic profile of different immune cell types, but only a few have also analysed the content of their delivered small extracellular vesicles (sEVs). The aim of the present study was to compare the protein signature of sEVs delivered from granulocytes (i.e., neutrophils and eosinophils) and CD4+ T cells (i.e., TH1, TH2, and TH17) to identify potential biomarkers of the inflammatory profile in chronic inflammatory diseases. Qualitative (DDA) and quantitative (DIA-SWATH) analyses of in vitro-produced sEVs revealed proteome variations depending on the cell source. The main differences were found between granulocyte- and TH cell-derived sEVs, with a higher abundance of antimicrobial proteins (e.g., LCN2, LTF, MPO) in granulocyte-derived sEVs and an enrichment of ribosomal proteins (RPL and RPS proteins) in TH-derived sEVs. Additionally, we found differentially abundant proteins between neutrophil and eosinophil sEVs (e.g., ILF2, LTF, LCN2) and between sEVs from different TH subsets (e.g., ISG15, ITGA4, ITGB2, or NAMPT). A “proof-of-concept” assay was also performed, with TH2 biomarkers ITGA4 and ITGB2 displaying a differential abundance in sEVs from T2high and T2low asthma patients. Thus, our findings highlight the potential use of these sEVs as a source of biomarkers for diseases where the different immune cell subsets studied participate, particularly chronic inflammatory pathologies such as asthma or chronic obstructive pulmonary disease (COPD).


  • Mepolizumab alters the phenotype and activation status of peripheral blood eosinophils in patients with severe eosinophilic asthma

    by Pablo Miguéns-Suárez, Sara Vázquez-Mera, Laura Martelo-Vidal, Uxío Calvo-Álvarez, Raquel Ruiz-Ferreras, Marina Blanco-Aparicio, Coral González-Fernández, Mar Mosteiro-Añón, María Dolores Corbacho-Abelaira, Paula Méndez-Brea, et al.

    Background: Severe eosinophilic asthma (SEA) is a T2high-endotype with recurrent exacerbations and poor disease control. Mepolizumab (anti-IL5 mAb) decreases the number of peripheral blood eosinophils, but the effect on their function is poorly understood. Our aim was to identify changes in the phenotype or activation of eosinophils in response to mepolizumab in patients with SEA. Methods: Blood samples were collected from healthy controls (HC; n=10) and SEA patients (n=12) before (T0) and after mepolizumab treatment (T4, 16, 32 weeks). Expression of proteins related to eosinophil activation (CD11b, CD44, CD48), immunomodulatory function (galectins 1/10), and eosinophil subsets, including resident (rEOS; CCR3+CD62LhiIL-3Rαlo) and inflammatory (iEOS; CCR3+CD62LloIL-3Rhi) eosinophils, were analyzed by flow cytometry. Results: Eosinophils from SEA display higher levels of Siglec-8, IL-5Rα, CD11b and CD44 (p<0.05) compared to HC, but no changes in regulatory proteins. Treatment with mepolizumab led to a decrease in eosinophil number (from 545.0 cells/μL at T0 to 133.1 cells/μL at T32; p<0.001) and a clear reduction of CD44 (p<0.01), together with a transition from rEOS to iEOS. All these changes were observed at early time point (T4) and maintained at T32. Conclusions: The number and activation status of eosinophils in peripheral blood is decreased by mepolizumab treatment and restored to HC levels. This treatment also induces a transition of iEOS to rEOS. Altogether, our results demonstrate a significant effect of mepolizumab on the function of eosinophils, which can be used as an indicator of response to this treatment. GSK provided funding for this study.